Interstitial lung disease (ILD), which often develops in systemic sclerosis (SSc), is associated with a better prognosis than idiopathic usual interstitial pneumonia (UIP) because only a limited number of patients with SSc progress to end stage fibrosis. Mechanisms driving the fibrotic evolution of ILD are still poorly understood, but, recently, on the basis of animal models, a pathogenetic role has been ascribed to an imbalance in the local Th1/Th2 response, with an expansion of the Th2 profile
Systemic sclerosis (SSc) is a complex, multi-organ, autoimmune disease. Lung fibrosis occurs in ~80%...
Understanding of the cellular and cytokine interactions associated with inflammation and fibrosis in...
In this pilot study, we aim to determine differences in pathogenetic pathways between interstitial p...
Interstitial lung disease (ILD), which often develops in systemic sclerosis (SSc), is associated wi...
BACKGROUND AND AIM: Fibrosing alveolitis develops in up to 80% of systemic sclerosis patients (SSc) ...
OBJECTIVE: The pathophysiology of the lung fibrotic process in systemic sclerosis (SSc) is not fully...
Systemic sclerosis (SSc) is a complex, multiorgan, autoimmune disease. Lung fibrosis occurs in ∼80% ...
Introduction: So far no clinical or experimental evidences clearly explain how and which systemic sc...
This study was designed to investigate the levels of IL-2 and its soluble receptor (sIL-2R) in bronc...
In systemic sclerosis (SSc), interstitial lung disease (ILD) is common (>80%) and worsens the pro...
Interstitial lung disease (ILD) is a debilitating complication of systemic sclerosis (SSc) and now t...
AbstractPatients with scleroderma (systemic sclerosis—SSc) frequently develop an interstitial lung d...
Various cytokines are known to participate in the pathogenesis of interstitial pneumonia follewed by...
Idiopathic pulmonay fibrosis (IPF), extrinsic alergic alveolitis (EAA) and sarcoidosis are interstit...
Interstitial lung disease (ILD) encompasses a large and diverse group of pathological conditions tha...
Systemic sclerosis (SSc) is a complex, multi-organ, autoimmune disease. Lung fibrosis occurs in ~80%...
Understanding of the cellular and cytokine interactions associated with inflammation and fibrosis in...
In this pilot study, we aim to determine differences in pathogenetic pathways between interstitial p...
Interstitial lung disease (ILD), which often develops in systemic sclerosis (SSc), is associated wi...
BACKGROUND AND AIM: Fibrosing alveolitis develops in up to 80% of systemic sclerosis patients (SSc) ...
OBJECTIVE: The pathophysiology of the lung fibrotic process in systemic sclerosis (SSc) is not fully...
Systemic sclerosis (SSc) is a complex, multiorgan, autoimmune disease. Lung fibrosis occurs in ∼80% ...
Introduction: So far no clinical or experimental evidences clearly explain how and which systemic sc...
This study was designed to investigate the levels of IL-2 and its soluble receptor (sIL-2R) in bronc...
In systemic sclerosis (SSc), interstitial lung disease (ILD) is common (>80%) and worsens the pro...
Interstitial lung disease (ILD) is a debilitating complication of systemic sclerosis (SSc) and now t...
AbstractPatients with scleroderma (systemic sclerosis—SSc) frequently develop an interstitial lung d...
Various cytokines are known to participate in the pathogenesis of interstitial pneumonia follewed by...
Idiopathic pulmonay fibrosis (IPF), extrinsic alergic alveolitis (EAA) and sarcoidosis are interstit...
Interstitial lung disease (ILD) encompasses a large and diverse group of pathological conditions tha...
Systemic sclerosis (SSc) is a complex, multi-organ, autoimmune disease. Lung fibrosis occurs in ~80%...
Understanding of the cellular and cytokine interactions associated with inflammation and fibrosis in...
In this pilot study, we aim to determine differences in pathogenetic pathways between interstitial p...